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Background/Aims: The findings of several recent studies 
suggest that antinuclear antibodies (ANAs) are frequently de-
tected in patients with acute hepatitis A (AHA). However, the 
clinical signiﬁ  cance of a positive ANA test remains uncertain. 
This study was performed to evaluate the clinical signiﬁ  cance 
of ANAs in AHA patients. Methods: All patients admitted with 
AHA were consecutively enrolled in this study. An ANA as-
say was performed by indirect immunofluorescence during 
hospitalization. ANA positivity was defined as an ANA titer 
≥1:80. The peak international normalized ratio (INR), peak 
alanine aminotransferase (ALT) and peak bilirubin levels 
were assessed over the duration of the hospitalization, and 
the incidence of AHA complications was evaluated. Results: 
A total of 422 patients were enrolled in this study (age, 31±7 
years), of which 260 (61.6%) were men. ANAs were detected 
in 179 AHA patients (42.4%). The proportion of ANA-positive 
patients varied signiﬁ  cantly with AHA status on the day of the 
ANA assay (4.7% during the prodromal period vs 52.1% dur-
ing the icteric or recovery period, p<0.001) and sex (56.2% 
in women vs 33.8% in men, p<0.001). The ANAs became un-
detectable in all ANA-positive patients within 3 months. The 
incidence of complications, including mortality, fulminant 
hepatic failure, renal dysfunction, relapse, and cholestatic 
hepatitis, did not differ significantly between ANA-positive 
and ANA-negative patients. Conclusions: ANAs were detect-
ed frequently and transiently in patients with AHA, especially 
after their peak-ALT day. The presence of ANAs may not be 
associated with the clinical outcome of AHA, but simply with 
AHA status on the ANA assay day. (Gut Liver 2011;5:340-347)
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INTRODUCTION
Antinuclear antibody (ANA), one of the non-organ-specific 
autoantibodies, is widely used in screening for and monitor-
ing of autoimmune hepatitis and other autoimmune disorders. 
However, ANA is detectable under conditions not related to au-
toimmune disorders, such as bacterial or viral infections.
1,2 Fur-
thermore, ANA-positive serum is found in about 5% of healthy 
populations.
3
Positive ANA tests, based on multiple reports, have been 
reported in 7% to 63% of patients with chronic hepatitis C.
4-10 
Although various studies have attempted to define the clinical 
significance of ANA in these patients, this significance remains 
to be clearly defined. Some authors suggest that ANA-positive 
serum in patients with chronic hepatitis C is associated with a 
more severe disease state,
5-8 while others failed to find any clini-
cal significance.
9,10
Currently, acute hepatitis A (AHA) is the most common cause 
of acute hepatitis in Korea.
11 AHA is a self-limiting disease, and 
so the symptoms of most patients resolve without any compli-
cations. However, serious complications including fulminant 
hepatic failure or renal dysfunction could develop in some 
patients. Meanwhile, several studies have suggested that tran-
sient ANA detection is not rare during the course of AHA.
12,13 
In addition, several authors have reported cases of autoimmune 
hepatitis triggered by AHA.
14-19 However, the precise role of 
ANA-results in the clinical outcomes of AHA has yet to be fully 
elucidated. Therefore, this study was performed to elucidate the 
role of ANA-positive results in the clinical outcomes of AHA.Seo YS, et al: Antinuclear Antibody in Acute Hepatitis A  341
MATERIALS AND METHODS
1. Patients
All patients with AHA who were admitted with AHA to the 
participating hospitals (Korea University Anam Hospital and 
Korea University Guro Hospital, Seoul, Korea) between Sep-
tember 2007 and August 2009 were consecutively enrolled in 
this study. AHA was diagnosed when patients were found to be 
positive for the hepatitis A virus IgM antibody and had a serum 
alanine aminotransferase (ALT) level of ≥400 IU/L. Patients were 
hospitalized if they suffered from general weakness and/or poor 
oral intake because of severe nausea and/or anorexia.
Day 0, defined as the day of acute hepatitis-associated symp-
tom onset, was determined by a thorough patient history. Blood 
tests, including serum ALT and bilirubin (BIL), and international 
normalized ratio (INR), were performed for each patient every 2 
to 3 days until peak levels of all parameters were identified. The 
course of AHA was divided into three periods as follows:
20 
1) The prodromal period, defined as the period before serum 
ALT levels peaked (peak-ALT day). The serum levels of both 
ALT and BIL increased during this phase.
2) The icteric period, defined as the period after the peak-ALT 
day and before the day that serum BIL levels peaked (peak-BIL 
day). The serum ALT levels decreased but serum BIL levels con-
tinued to increase during in this phase.
3) The recovery period, defined as the period after the peak-
BIL day. The serum levels of both ALT and BIL decreased in this 
phase, but had not recovered to below the upper limit of nor-
mal.
Hospitalization day was considered as the peak-ALT day in 
patients who were hospitalized during the icteric or recovery 
periods, and as the peak-BIL day in patients who visited our 
hospitals during the recovery period.
The study protocol conformed to the ethical guidelines of the 
1975 Declaration of Helsinki and was approved by our Institu-
tional Review Board. Written informed consent to participate 
was obtained from each enrolled patient.
2. ANA assay
ANA assays were performed by indirect immunofluorescence 
on Hep-2 cells during patient hospitalization. ANA-positive 
serum was defined as ANA titers ≥1:80 because detection of 
low ANA titer is apparent even in the healthy population.
3 In 
ANA-positive patients, further ANA tests were performed every 
month until levels decreased to <1:80.
3. Clinical outcome of AHA
To evaluate whether the ANA data were associated with the 
clinical outcomes of AHA, peak serum ALT and BIL levels, 
peak INR, and the incidence of mortality or liver transplanta-
tion, fulminant hepatic failure, renal dysfunction, severe renal 
dysfunction requiring dialysis, relapse, and cholestatic hepatitis 
were evaluated. Serum ALT levels on the day of hospitalization 
were considered peak ALT levels in patients who were admitted 
during the icteric or recovery periods, and serum BIL levels on 
the hospitalization day were considered the peak BIL level in 
patients who visited our hospitals during the recovery period. 
Fulminant hepatic failure was defined as the development of 
encephalopathy, evidence of significant liver injury, and severe, 
prolonged prothrombin time without previous liver disease. 
Relapse was defined as a biphasic or second peak of serum ALT 
elevation after complete or partial resolution of the first ALT 
peak.
21 Cholestatic hepatitis was defined as a persistent elevation 
in serum BIL >2.5 mg/dL for more than 2 months after illness 
onset. Renal dysfunction was defined as a serum creatinine level 
>1.5 mg/dL.
4. Statistics
Statistical analyses were performed using the SPSS ver-
sion 13.0 (SPSS, Chicago, IL, USA). Data are expressed as 
mean±standard deviation (SD), or percentage values. Student’s 
t-test and the χ
2-test were used to compare group continuous 
and categorical variables, respectively. Binary logistic regression 
analysis was performed to identify those factors significantly 
associated with the ANA data. The level of statistical signifi-
cance was set at p<0.05 (two-sided).
RESULTS
1. Baseline characteristics
Table 1 presents the baseline characteristics for the 422 pa-
tients (age, 31±7 years; 61.6% men) who were admitted to our 
hospitals for treatment of AHA. Serum ALT level, BIL level, and 
INR on the day of hospitalization were 2,980±2,058 IU/L, 4.6±3.5 
mg/dL, and 1.3±0.4, respectively. Patients visited our hospitals 
at 5±3 days after day 0. The AHA status on the day of hospital-
ization was the prodromal period in 122 patients (28.9%), the 
icteric period in 146 patients (34.6%), and the recovery period in 
154 patients (36.5%).
Patients were hospitalized for 9±6 days. The serum ALT level, 
BIL level, and INR reached peak values of 3,508±2,130 IU/L, 
7.4±4.4 mg/dL, and 1.4±0.6, respectively, at 6±2, 10±5, and 6±3 
days after day 0. Fulminant hepatic failure developed in 10 pa-
tients (2.4%), and 7 patients (1.7%) died during hospitalization 
(n=6) or received liver transplantation for fulminant hepatic 
failure (n=1). Renal dysfunction developed in 30 patients (7.1%) 
and dialysis was needed in 13 (3.1%). Relapse and cholestatic 
hepatitis were noted in 3 (0.7%) and 22 (5.2%) patients, respec-
tively.
2. Results of ANA testing
Patients were hospitalized at 5±3 days after day 0 and tested 
for ANA at 6±3 days after day 0 (1±1 days after hospitaliza-
tion). The AHA status on the day of the ANA assay (ANA-assay 342  Gut and Liver, Vol. 5, No. 3, September 2011
day) was the prodromal period in 86 patients (20.4%), the icteric 
period in 176 patients (41.7%), and the recovery period in 160 
patients (37.9%). 
Of all AHA patients, 179 were observed as ANA-positive 
(42.4%). ANA titers were negative in 162 patients (38.4%), 1:40 
in 81 patients (19.2%), 1:80 in 94 patients (22.3%), 1:160 in 
76 patients (18.0%), 1:320 in 7 patients (1.7%), and 1:640 in 2 
patients (0.5%). The proportion of ANA-positive patients varied 
significantly with AHA status on the ANA-assay day; it was 
significantly lower in the prodromal period (4 of 86 patients, 
4.7%) than in the icteric (87 of 176 patients, 49.4%; p<0.001) 
and recovery (88 of 160 patients, 55.0%; p<0.001) periods, 
while it did not differ between the icteric period and recovery 
period (p=0.308, Fig. 1).
Therefore, all patients were classified into two groups accord-
ing to their AHA status on the ANA-assay day. Group I was 
consisted of patients who underwent ANA testing during the 
prodromal period (i.e., before the peak-ALT day); and group II 
was comprised of patients who underwent ANA testing during 
the icteric or recovery periods (i.e., after the peak-ALT day). The 
distribution of titers differed significantly between groups I and 
II (p<0.001, Fig. 2). ANA-positive results were more frequent 
among women (91 of 162 women, 56.2%) than men (88 of 260 
men, 33.8%; p<0.001). Serum BIL levels on the ANA-assay 
day were significantly higher in ANA-positive than in ANA-
negative patients (6.0±3.5 mg/dL vs 4.0±3.0 mg/dL, respec-
tively; p=0.003) and in serum ALT level on the ANA-assay day 
(2,471±1,670 IU/L vs 3,011±2,020 IU/L, respectively; p=0.003). 
Peak serum levels of ALT (3,195±2,037 IU/L vs 3,739±2,172 IU/L, 
respectively; p=0.009) were significantly lower in ANA-positive 
than in ANA-negative patients. However, peak serum BIL levels 
(7.8±4.3 mg/dL vs 7.2±4.5 mg/dL; p=0.146) did not differ be-
tween ANA-positive and ANA-negative patients (Table 1).
Multivariate analysis revealed that testing for ANA during 
the icteric or recovery periods (β, 3.218; odds ratio [OR], 24.971; 
95% confidence interval [CI], 7.869 to 79.237; p<0.001], being 
female (β, 1.319; OR, 3.741; 95% CI, 2.263 to 6.186; p<0.001), 
higher serum ALT (β, 0.000; OR, 1.000; 95% CI, 0.999 to 1.000; 
p<0.001) and BIL levels (β, 0.171; OR, 1.186; 95% CI, 1.092 to 
1.289; p<0.001) on the ANA-assay day, and a higher peak ALT 
level (β, 0.000; OR, 1.000; 95% CI, 1.000 to 1.001; p=0.006) 
were significantly associated with ANA-positive status.
Fig. 1. Proportion of antinuclear antibody (ANA)-positive patients 
with acute hepatitis A according to AHA status on the ANA assay day. 
AHA, acute hepatitis A.
Table 1. Baseline Characteristics of Patients with AHA Relative to the ANA Results
Characteristic All (n=422) ANA-negative (n=243) ANA-positive (n=179) p-value
Age, yr  31.1±6.5ɹ   30.9±6.1ɹ   31.3±7.1ɹ 0.563
Males, n (%) 260 (61.6)   172 (70.8)ɹ 88 (49.2) <0.001
HBsAg positivity, n (%) 15 (3.6) 9 (3.7) 6 (3.4) 0.847
The course of AHA at the initial ANA-assay day <0.001
  Prodromal period, n (%)   86 (20.4) 82 (33.7) 4 (2.2)
  Icteric period, n (%) 176 (41.7) 89 (36.6) 87 (48.6)
  Recovery period, n (%) 160 (37.9) 72 (29.6) 88 (49.2)
ALT level on ANA-assay day, IU/L 2,766±1,899 3,011±2,020 2,471±1,670 0.003
BIL level on ANA-assay day, mg/dL 4.9±3.4 4.0±3.0 6.0±3.5 <0.001
INR on ANA-assay day 1.3±0.4 1.3±0.4 1.3±0.4 0.462
Peak ALT level, IU/L 3,508±2,130 3,739±2,172 3,195±2,037 0.009
Peak BIL level, mg/dL 7.4±4.4 7.2±4.5 7.8±4.3 0.146
Peak INR 1.4±0.6 1.4±0.6 1.4±0.5 0.393
Duration of hospitalization, day 9±6 9±6 9±5 0.493
AHA, acute hepatitis A; ANA, antinuclear antibody; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; BIL, bilirubin; INR, inter-
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3. Subgroup analysis with patients admitted during the pro-
dromal phase
ANA results were significantly associated with AHA status 
on the ANA-assay day, sex, and also with serum ALT and BIL 
levels on the ANA-assay day and peak ALT level. However, 
the peak ALT level in group II patients could not be considered 
their true peak level. In addition, serum ALT and BIL levels on 
the ANA-assay day might simply reflect AHA status. Therefore, 
to exclude these potentially confounding factors, a subgroup 
analysis with 122 patients who were hospitalized during the 
prodromal period was performed. The age of this subgroup was 
31.5±5.6 years, and 86 (70.5%) were men. Hepatitis B surface 
antigen was present in 4 patients (3.3%). The ALT level, BIL lev-
el, and INR were 2,230±2,168 IU/L, 2.0±1.6 mg/dL, and 1.3±0.4 
at baseline, respectively, and peaked to 4,114±2,428 IU/L, 7.8±5.2 
mg/dL, and 1.6±0.8, respectively, at 5±2, 11±6, and 5±3 days 
after day 0. 
The ANA assay was performed 4±2 days after day 0 and at 
-1±2 days from the peak-ALT day. The AHA status on the ANA-
assay day was the prodromal period in 86 patients (70.5%, group 
I) and the icteric period in 36 (29.5%, group II). ANA-positive re-
sults were found in 25 patients (20.5%). The prevalence of ANA-
positive results did not differ significantly between men (12 of 
76 men, 15.8%) and women (13 of 46 women, 28.3%; p=0.098). 
ANA-positive patients occurred more frequently in group II (21 
of 36 patients, 58.3%) than in group I (4 of 86 patients, 4.7%; 
p<0.001). Serum BIL levels (2.7±2.2 mg/dL vs 3.9±2.1 mg/dL, 
p=0.018) on the ANA-assay day differed significantly between 
ANA-negative and ANA-positive patients, while serum ALT lev-
el on the ANA-assay day and peak ALT and BIL levels did not 
differ (Table 2). Only the results of ANA assays performed dur-
ing the icteric or recovery periods were significantly associated 
with the ANA data according to multivariate analysis (β, 3.357; 
OR, 38.700; 95% CI, 8.622 to 95.535; p<0.001).
Table 2. Baseline Characteristics and Clinical Outcomes of Patients with AHA Who Visited Hospitals during the Prodromal Phase Relative to the 
ANA Results
Characteristic ANA-negative (n=97) ANA-positive (n=25) p-value* p-value
̈
Age, yr 31.1±5.5 33.1±5.9 0.119
Male, n (%) 64 (66.0) 12 (48.0) 0.098
HBsAg positivity, n (%) 3 (3.1) 1 (4.0) 0.820
ANA assay during the prodromal period, n (%) 82 (84.5)   4 (16.0) <0.001 <0.001
Results on the ANA-assay day
  Serum ALT level, IU/L 2,655±1,960 3,026±2,239 0.415
  Serum BIL level, mg/dL 2.7±2.2 3.9±2.1 0.018 0.827
  INR 1.4±0.5 1.4±0.6 0.828
Peak values of
  Serum ALT level, IU/L 4,065±2,283 4,301±2,971 0.667
  Serum BIL level, mg/dL 7.8±5.1 7.8±5.7 0.991
  INR 1.6±0.9 1.5±0.5 0.480
HBsAg, hepatitis B surface antigen; ANA, antinuclear antibody; ALT, alanine aminotransferase; BIL, bilirubin; INR, international normalized ratio.
*Univariate analysis; 
̈Multivariate analysis.
Fig. 2. Distribution of antinuclear 
antibody (ANA) titers in patients 
with acute hepatitis A. Group I, pa-
tients who underwent ANA testing 
during the prodromal period; Group 
II, patients who underwent ANA 
testing during the icteric or recovery 
periods.344  Gut and Liver, Vol. 5, No. 3, September 2011
4. Effect of ANA-positive status on the incidence of AHA 
complications
The incidence of death or liver transplantation (1.6% vs 1.7%, 
p=0.981), fulminant hepatic failure (2.5% vs 2.2%, p=0.876), 
renal dysfunction (8.2% vs 5.6%, p=0.296), severe renal dys-
function requiring dialysis (4.1% vs 1.7%, p=0.152), relapse 
(0.4% vs 1.1%, p=0.391), and cholestatic hepatitis (4.1% vs 
6.7%, p=0.232) did not differ between ANA-negative and ANA-
positive patients. Since ANA results were significantly associ-
ated with sex and AHA status on the ANA-assay day, regression 
analysis was performed to evaluate the relationship between 
ANA findings and the clinical outcome of AHA adjusted for sex 
and AHA status on the ANA-assay day. There was no signifi-
cant relationship found between ANA-positive results and any 
clinical outcome (Table 3).
5. Changes in ANA ﬁ  ndings after AHA resolution
The ANA assay was repeated 0.8±1.0 times in 179 ANA-
positive patients at baseline. A follow-up ANA assay repeated 1 
month after symptom onset in 92 of 179 ANA-positive patients 
(51.4%) revealed a decrease in ANA titer in 89 patients (96.7%), 
no change in 1 patient (1.1%), and an increase in 2 patients 
(9.8%; from 1:80 to 1:160 in 1 patient and from 1:80 to 1:320 
in the other). Among the 89 patients with decreased ANA titer 
after 1 month, the ANA titer was ≤1:40 in 58 patients. An ad-
ditional ANA assay was repeated the next month in 21 (61.8%) 
of the 34 patients with an ANA titer ≥1:80 after 1 month, which 
revealed a decrease in ANA titer in 20 patients (95.2%) with no 
change in the remaining patient (4.8%). ANA titer was ≥1:80 
2 months after the first ANA assay on day 0 in only 3 patients 
(ANA titers were 1:80 in all 3 patients), but this decreased to 
≤1:40 in all 3 patients by 3 months after the first assay on day 
0 (Fig. 3).
6. Dynamic changes in ANA titer during the course of AHA 
in patients with a baseline ANA titer ≤1:40
ANA tests were performed several times every 1 to 2 weeks 
in seven patients whose baseline ANA titers were ≤1:40 (Fig. 
4). Baseline ANA tests were performed at 4±1 days (median, 4 
days; range, 2 to 5 days) from day 0 and at -1±1 days (median, 
-1 day; range, -2 to 1 days) from peak-ALT days. Baseline ANA 
was negative in 2 patients and 1:40 in 5 patients. In all patients, 
Table 3. Regression Analysis of the Relationship between ANA Results and the Incidence of AHA Complications
Complication β OR (95% CI) p-value*
Death or liver transplantation 0.670 1.954 (0.287–13.302) 0.494
Fulminant hepatic failure 0.317 1.373 (0.284–6.653) 0.693
Renal dysfunction –0.158 0.854 (0.364–2.005) 0.717
Severe renal dysfunction –0.462 0.630 (0.158–2.518) 0.513
Relapse 1.963 7.120 (0.317–159.685) 0.216
Cholestatic hepatitis 0.943 2.568 (0.945–6.975) 0.064
OR, odds ratio; CI, confidence interval.
*Adjusted for sex and AHA status.
Fig. 3. Change in the distribution of antinuclear antibody (ANA) titers 
in patients with acute hepatitis A during a 3-month follow-up period.
Fig. 4. Antinuclear antibody (ANA) assay findings during the course 
of acute hepatitis A in seven patients whose baseline ANA titers are 
≤1:40. 
ALT, alanine aminotransferase.Seo YS, et al: Antinuclear Antibody in Acute Hepatitis A  345
ANA-positivity was found in the second ANA assay, which was 
performed at 10±2 days (median, 10 days; range, 8 to 13 days) 
after day 0 and at 6±2 days (median, 5 days; range, 3 to 9 days) 
after peak-ALT day, and then progressively decreased. Peak 
ANA titer was 1:80 in 3 patients, 1:160 in 3 patients, and 1:320 
in 1 patient. ANA titers decreased to ≤1:40 at 37±12 days (me-
dian, 35 days; range, 23 to 59 days) after day 0 and at 33±12 
days (median, 29 days; range, 19 to 55 days) after the peak-ALT 
day.
DISCUSSION
The results of several previous studies suggest that ANA can 
be detected in non-autoimmune conditions such as bacterial or 
viral infections.
1,2 In addition, ANA positivity was frequently 
found in patients with AHA.
12,13,22 Therefore, it was not surpris-
ing that ANA was frequently detected in patients with AHA 
in the present study. However, previous studies did not fully 
elucidate whether transient detection of ANA could be associ-
ated with clinical outcomes of AHA. In this context, our results 
indicate the clinical significance of ANA-positive results in 
AHA because a large number of patients with various AHA 
statuses were enrolled. ANA was detected frequently in patients 
with AHA, especially after the peak-ALT day, and disappeared 
within 3 months in most cases. In addition, ANA-positivity was 
not associated with the clinical outcomes of AHA (peak ALT 
and bilirubin levels, duration of hospitalization, and incidence 
of complications), but was associated with sex and the course of 
AHA on the ANA-exam day.
In this study, a significant number of patients was hospital-
ized during the AHA prodromal period. Patients typically do not 
know that they have AHA during the prodromal period because 
symptoms in this period are nonspecific, including fever, chill, 
nausea, and abdominal pain. However, because of an AHA 
outbreak in Korea during our study period,
23 interest in AHA in-
creased among the general population and many people visited 
the hospital to be assessed for the condition if they had a fever 
or chill. Therefore, AHA patients were diagnosed and hospital-
ized during the prodromal period.
A recent study found ANA-positive sera in 89% of patients 
with AHA,
13 which was slightly higher than that found in the 
present study, even if low ANA titer (1:40) was considered 
ANA-positive (61.6%). This discrepancy between the two stud-
ies may be attributable to differences in patient’s AHA status on 
the ANA-assay day, but information regarding AHA status on 
the ANA-assay day was not available in the recently published 
study.
13 If patients who underwent ANA testing during the 
prodromal period were excluded from this study, the incidence 
of ANA-positive patients would have been 73.5% (247 of 336 
patients). Another discrepancy between these two studies was 
the sex distribution; 52.5% of all enrolled patients were women 
in the recent study,
13 while that figure was 38.4% in the present 
study. ANA titers were ≥1:40 in 82.1% of women and 67.8% of 
men among patients who underwent ANA testing during the ic-
teric or recovery periods. Our results suggest that the prevalence 
of ANA in patients with AHA varies according to the proportion 
of women in the cohort and to the AHA status on the ANA-
assay day.
In non-autoimmune conditions, ANA-positive results have 
been shown to be associated with sex and age.
3,24-26 Moreover, 
women in general are two to three times more likely to develop 
autoimmune diseases.
27 Although the mechanism underlying 
the relationship between sex and autoimmunity remains un-
clear, it is believed that hormones such as estrogen may play 
an important role.
28 Similarly, the etiology of the relationship 
between age and ANA-positive status is uncertain, but it might 
reflect a characteristic of the ageing immune system.
10 The age-
dependent increase in the frequency of autoimmune antibodies 
may be attributable to repeated stimulation with bacteria or 
viruses.
3
Consistent with previous findings,
3,24-26 ANA-positive results 
in the present study were more prevalent among women than 
men, and being female was independently associated with 
ANA-positive status. However, the difference between the sexes 
did not reach statistical significance in the subgroup of patients 
admitted during the prodromal period, which may be explained 
by the relatively small number of ANA-positive patients (20.5%) 
and small number of women (37.7%) in this subgroup. In con-
trast, age did not differ significantly between ANA-positive and 
ANA-negative patients in this study. In previous studies, an 
age-dependent variable in ANA-positive status was noted; espe-
cially among patients older than 40 to 60 years.
3,25,26 Most of the 
patients in this study were young (87.7% of patients in the third 
or fourth decade of life) and only 33 patients (7.8%) were older 
than 40 years. This narrow age range and the relative youth of 
our patients might explain the lack of an association between 
age and ANA-positive results in this study.
It has been reported that ANA was detected in 7% to 35% of 
patients with chronic hepatitis C.
4-10 However, it is still unclear 
whether ANA-positive status in chronic hepatitis C is the cause 
of more severe disease. Some authors suggest that ANA-positive 
status is associated with higher aminotransferase levels,
5-7 in-
creased severe inflammation,
6 or advanced fibrosis,
8 while oth-
ers have found no such difference.
9,10 Meanwhile, several studies 
suggest that ANA-positive status has no clinical impact in pa-
tients with AHA because all patients had a favorable course and 
ANA titer decreased or disappeared within several months.
12,13 
Gutiérrez et al.
12 suggested that the presence of ANA is the re-
sult of a non-specific immunological response to viral infection. 
However, due to the small number of enrolled patients and the 
limited information about their AHA status in these studies, the 
clinical significance of ANA in AHA could not be confirmed. In 
our study, the clinical outcomes, including peak ALT and BIL 
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complications, were analyzed relative to the ANA findings to 
evaluate the clinical significance of ANA. 
Comparisons of peak ALT and BIL levels were analyzed us-
ing only patients who were hospitalized during the prodromal 
period. Since the results of ANA testing were significantly as-
sociated with both sex and AHA status on ANA-assay day, the 
analysis was conducted after adjustment for these two variables. 
The clinical outcomes of AHA did not differ significantly be-
tween ANA-positive and ANA-negative patients. In addition, 
consistent with the findings of previous studies,
12,13 ANA titer 
reached ≤1:40 or decreased to negative within 3 months after 
the onset of AHA in almost all patients with a baseline ANA ti-
ter ≥1:80. Therefore, it was concluded that ANA-positive status 
during AHA is transient and does not have any clinical impact 
on the course of the disease.
Several authors have reported cases of autoimmune hepatitis 
triggered by AHA and suggested that AHA actually precipitates 
autoimmune hepatitis.
14-19 As a potential mechanism, a previ-
ous study suggested that T-helper cells reactive to hepatitis A 
virus antigens exposed on the surface of infected hepatocytes 
provide help for autoreactive B cells specific for an antigen (the 
asialoglycoprotein receptor) that is coexpressed on the hepato-
cyte membrane.
14 In previous cases,
14-19 autoimmune hepatitis 
developed 2 to 3 months after the onset of AHA, while ANA-
positive status disappeared within 3 months after AHA onset in 
the present study. Our results are consistent with the previous 
finding that ANA titer decreased or disappeared within several 
months in all enrolled patients.
12,13 
In conclusion, ANA-positive sera were detected frequently 
and transiently in patients with AHA, especially after the peak-
ALT day. ANA-positive status might not be associated with the 
clinical outcome of AHA, but simply with AHA status on the 
ANA-assay day.
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